| Similar Articles |
|---|
 |
Chemistry World
July 3, 2014
Maria Burke |
Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.   |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
Chemistry World
December 10, 2014 |
Big pharma opens up abandoned drugs Sixty eight stalled pharmaceutical compounds are being made available for academic research through the UK Medical Research Council. |
AskMen.com
Jacob Franek |
Future Cures Almost every disease known to man is under constant research and we can hardly go a day without hearing about some advancement or another. Here are a few diseases for which future cures could be looming on the horizon. |
Chemistry World
December 16, 2013
Michael Parkin |
1024 samples analysed on a single chip Researchers in Switzerland have developed a microfluidic platform able to measure four protein biomarkers in over 1000 blood samples on a single microfluidic chip. |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
Chemistry World
April 21, 2008
Pete Mitchel |
The hunt for metabolic biomarkers In the largest metabonomics study ever carried out, researchers have discovered strong correlations between individuals' blood pressure and the levels of certain metabolites in their urine. |
Bio-IT World
March 8, 2005
Patricia Reilly |
Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending. |
BusinessWeek
June 6, 2005
Catherine Arnst |
The Anti-Cancer Strategist Oncology specialist Judah Folkman pioneered a new treatment: Starve the tumor |
Chemistry World
January 21, 2011
Jennifer Newton |
Early lung cancer diagnosis Patients with lung cancer have elevated levels of a specific protein in their blood that could be used as a biomarker for the disease, say scientists from South Korea. |
| AskMen.com |
Cholesterol & The Prostate A new study suggests that men may be able to lower their risk of getting the most aggressive form of prostate cancer by keeping their cholesterol in a healthy range. |
Fast Company
Christina Farr |
AHA, Alphabet Set Aside $75 Million To Cure Coronary Heart Disease The American Heart Association, Verily (the company formerly known as Google Life Sciences), and European pharmaceutical giant AstraZeneca are investing the funds over a five-year period. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Chemistry World
August 1, 2012
Patrick Walter |
Phenomenal Olympic science legacy (or is that sustainability?) What do you do with a lab set up solely to catch Olympic drug cheats once the games are over? In the case of the London 2012 games, the answer is to turn it into a state of the art analytical lab. |
Reactive Reports
Issue 55
David Bradley |
Testing the Byproducts of Cell Death A new approach to testing whether a particular chemotherapy agent is working well in treating a patient's cancer is being developed by UK scientists |
Chemistry World
November 16, 2011
Helen Potter |
Early diagnosis for Alzheimer's and Parkinson's US scientists have developed a biosensor that could detect the early stages of Alzheimer's disease and Parkinson's disease by measuring low concentrations of protein aggregates in cerebrospinal fluid. |
BusinessWeek
March 8, 2004
Arlene Weintraub |
And When ImClone's Drug Doesn't Work... Physicians have greeted ImClone Systems Inc.'s (IMCL ) cancer drug, Erbitux, with a mixture of glee and grim realism. The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect -- and no one knows why. |
Scientific American
June 2006
Philip Yam |
The Ultimate Blood Test A pricey way to determine health risks: the Biophysical 250 assessment, a series of 250 blood tests done at one time. |
Bio-IT World
April 2007
Malorye Allison |
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? |
Managed Care
February 2008
Thomas Morrow |
As the Use of Biomarkers Grows, Managed Care Companies Will Face Tough Decisions About Setting Limits Health care faces difficult challenges as it increasingly incorporates a personalized approach that uses various biomarkers to influence medical decision-making. |
American Family Physician
March 15, 2006
Liz Smith |
Newsletter CDC Recommends Increased Influenza Vaccination in Health Care Staff... Health Initiative to Improve Cancer Therapy with Biomarker Evaluation... Pharmaceutical Association Supports Lower Priced Drugs Act... etc. |
Pharmaceutical Executive
December 1, 2013 |
FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler. |
Chemistry World
February 2, 2015
Emma Stoye |
UK announces 40m fund for synthetic biology The UK government has said it will invest 40 million pounds in synthetic biology over the next five years, 32 million of which will be used to establish three new research centers. |
Bio-IT World
August 13, 2003
Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm. |
Chemistry World
August 30, 2009
Nina Notman |
Nanoparticle breath test for lung cancer A sensor that can differentiate between the volatile organic compounds in the breath of lung cancer patients and those of healthy people has been developed by scientists in Israel. |
Chemistry World
November 8, 2006
Victoria Gill |
Molecular Signals of Schizophrenia Identified Researchers have identified specific biomarkers for schizophrenia, a discovery which could pave the way to more accurate diagnostics, improved treatments, and could even be the starting point for the development of preventative medicines. |
BusinessWeek
June 6, 2005 |
Inside Judah Folkman's Lab The pioneering cancer researcher, Dr. Judah Folkman, talks about the path that led to his discoveries and about how much remains to be done |
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler |
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? |
Bio-IT World
May 2006 |
News Blast Aids Action... Oxford Universal... Myriad Options... |
Chemistry World
July 18, 2008
James Mitchell Crow |
New drug test misses Olympic deadline A biomarker-based test has been developed to detect athletes that have used banned drugs long after the compounds themselves become undetectable - but it won't be approved in time for the Beijing Olympics. |
Pharmaceutical Executive
May 1, 2006
Jill Wechsler |
Washington Report: Opportunity Knocks FDA has finally released its long-awaited list of research opportunities for the Critical Path initiative. Now comes the hard part, as companies learn how to collaborate on projects that will benefit pharma as a whole. |
Pharmaceutical Executive
November 1, 2008
Jill Wechsler |
Resolving Conflicting Interests The Physician Payment Sunshine Act would require pharmaceutical and medical device companies to disclose payments of more than $500 to doctors. |
Pharmaceutical Executive
May 1, 2007
Weiner & Hovde |
Critical Mass for Critical Path? Everyone agrees that it's the road to pharma's future, but no one's rushing to take it. Yet with growing FDA advocacy and new advances in biomarkers and drug-disease modeling, the rewards of collaboration now look greater than the risks. |
Chemistry World
January 15, 2014
Kirsty Muirhead |
Biomarkers leave gender clues at crime scene Scientists in the US have unveiled details of a colorimetric assay that could provide an initial indication of a suspect's gender during the on-scene stages of a forensic investigation. |
